🔗 Share this article

While the United States proceeds with sweeping changes to its vaccine guidelines, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who first made her name by casting doubt on Covid vaccinations during the global health crisis and has concentrated on possible deaths following COVID-19 vaccination in her recent tenure at the Food and Drug Administration.

Planned Changes to Pediatric Immunization Program

Agency leaders had intended to announce sweeping changes to the childhood vaccine schedule earlier this month, bringing the US with Denmark’s vaccine program, sources say – a significant shift that would put the US out of alignment with a large portion of the international standard with insufficient data for improved outcomes. The planned update has been postponed until the new year.

Rather than the director of the vaccine center, Tracy Beth Høeg is listed to address the audience at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the division this year.

A New Direction at the Agency

Høeg's temporary position might represent a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Prasad strengthen their influence at the FDA – and it signals a increased emphasis upon dismantling long-standing vaccines at the FDA.

The new acting director has frequently advocated for halting certain pediatric immunization guidelines in the US to become more similar to the Danish model, a country with universal health coverage and a population roughly the population of Wisconsin’s.

To date statements, she has continued to focus on immunizations – traditionally the domain of Dr. Prasad, chief of the FDA’s CBER – instead of medication approval.

Doubts Over Expertise

Høeg has no obvious track record in medication creation, oversight or management, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, said a neurologist and psychiatrist. “She’s never run a clinical trial. She lacks experience in running a large organization. She has no expertise in pharmaceutical oversight.”

Past commissioners of the center would “grasp legal statutes and the underlying principles of drug development”, noted Dr. Janet Woodcock. “Frankly, she lacks the kind of background that former directors who led the center have had.”

This division has an enormous portfolio at the agency, the former commissioner stated.

“Everybody just zeroes in on the novel medication approvals, but the generic program clears a multitude of generic drugs. There is also a biosimilars program, OTC medication office and other areas, and all of those have to be supervised,” she explained. “The thing you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Furthermore, a substantial management component to the job, which supervises in excess of 5,000 staff members. “It is a huge administrative position, if you perform it correctly,” Woodcock added.

Response and Disputed Policies

Regarding concerns about Dr. Høeg's fitness for the role and whether this assignment indicates greater collaboration among FDA leaders on vaccines, a representative responded that the “inquiries are based on inaccurate presumptions”.

“This background aligns with the functions of her role,” the representative explained, pointing to the period Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a contentious expedited therapy clearance system that apparently troubled her former heads. “How are these drugs being chosen for this expedited pathway? Who makes the calls?” Dr. Howard questioned. “There is a lot of confidentiality going on at the FDA right now.”

Overall, he stated, “the agency seems to be moving towards laxer regulations of pharmaceuticals, except for shots.”

Established Past Work on Immunizations

Concerning vaccines, Høeg has a more documented, if problematic, track record, some experts have noted. She published a analysis using non-validated public submissions to estimate the rate of myocarditis after COVID-19 immunization. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to indicate COVID-19 vaccinations are riskier than they are.

Among her “desired changes” for the incoming federal leadership featured altering regulations for new vaccines and halting “optional” vaccines, she said post-election on a podcast. At the FDA, Høeg has reportedly suggested excluding teenage boys from obtaining COVID-19 vaccines.

“She is an thorough dogmatist who starts off with her preconceived notions and works backwards to retrofit the science in a extremely disingenuous, dishonest manner,” Howard said.

Taking Control and a “Revenge Tour”

Høeg aligned with other contrarians, {like|